This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

MIROBIO RAISES $97M SERIES B TO DEVELOP CHECKPOINT AGONISTS FOR AUTOIMMUNE DISEASES

MIROBIO RAISES $97M SERIES B TO DEVELOP CHECKPOINT AGONISTS FOR AUTOIMMUNE DISEASES

29 Jun 2022

MIROBIO RAISES $97 MILLION SERIES B FINANCING TO DEVELOP CHECKPOINT AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASES Financing led by Medicxi with significant participation from new and existing shareholders Lead program MB272 targeting checkpoint receptor BTLA, entering Phase I clinical trials Funds will be used to advance pipeline of immune checkpoint agonists into clinical trials in autoimmune diseases OXFORD, United Kingdom, June 29... Read more

OMass Therapeutics Wins The Oxford Science Park Innovation Award at Oxfordshire Business Awards

OMass Therapeutics Wins The Oxford Science Park Innovation Award at Oxfordshire Business Awards

20 Jun 2022

Oxford, United Kingdom – 20 June 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to announce that it has won the Oxford Science Park Innovation Award at the Oxfordshire Business Awards. The Oxfordshire Business Awards recognise, reward and promote the excellence of Oxfordshire-based companies. OMass Therapeutics received the Oxford... Read more

Drug discovery company OMass Therapeutics is 2022 winner of TOSP's Innovation Award

Drug discovery company OMass Therapeutics is 2022 winner of TOSP's Innovation Award

18 Jun 2022

Work to discover drugs for rare and immunological diseases recognised as part of Oxfordshire Business Awards Oxford, UK, June 18 2022 – Its work in discovering medicines for rare and immunological diseases has earned OMass Therapeutics The Oxford Science Park Innovation Award 2022. Given as part of the Oxfordshire Business Awards, it recognises the company’s progress in generating a pipeline of small molecule therapeutics, discovered using... Read more

OxSonics strengthens management team with hire of Dr Marianna Lalla as Chief Medical Officer

OxSonics strengthens management team with hire of Dr Marianna Lalla as Chief Medical Officer

06 Jun 2022

OxSonics strengthens management team with appointment of Dr Marianna Lalla as Chief Medical Officer Underpins Company’s strategy to expand its pipeline of clinical combination studies Oxford, UK – 6th June 2022 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, is pleased to announce that Dr Marianna Lalla has joined the Company as Chief Medical Officer (CMO).... Read more

moa raises $44m Series B to Progress a New Generation of Safe, Sustainable Crop Protection Products

moa raises $44m Series B to Progress a New Generation of Safe, Sustainable Crop Protection Products

31 May 2022

Financing co-led by new investor Lansdowne Partners and existing investors Oxford Science Enterprises and Parkwalk Advisors, with BGF Investments, Bits x Bites Growth Fund, IP Group, and University of Oxford participating Investment will advance moa’s pipeline of new crop protection products designed to increase the resilience and security of the world’s food production system by tackling the urgent global... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More